Neuronetics Signs Exclusive Three-Year TMS Device Agreement With Elite DNA Behavioral Health

Neuronetics, Inc. a medical technology company specializing in innovative treatments for neurohealth disorders, has entered into an exclusive three-year agreement with Elite DNA Behavioral Health, one of Florida’s largest and fastest-growing mental health networks. Under this partnership, Neuronetics will serve as the sole provider of transcranial magnetic stimulation (TMS) devices across Elite DNA’s 30+ locations, supporting its mission to enhance access to advanced, noninvasive therapies for patients with depression and other mental health conditions.

“We are excited to further build upon our commercial partnership with Elite DNA Behavioral Health. Together, we’re expanding NeuroStar’s reach and helping even more patients access proven, life-changing TMS therapy through a scalable, systemized model of care,” said Keith J. Sullivan, President and CEO of Neuronetics. “This collaboration operationalizes one of the stated strategic values of the Greenbrook acquisition and offers a model for delivering this service to other organizations in the future.”

The collaboration extends beyond device supply, incorporating Neuronetics’ Greenbrook platform to deliver a range of fee-based operational and patient-support services. Through a newly established subsidiary, Neuronetics will assist Elite DNA with key administrative and clinical functions such as PHQ-10 assessments, TMS consultations, and patient scheduling. Leveraging Greenbrook’s specialized infrastructure allows Elite DNA to streamline back-end operations and dedicate more resources toward patient care and experience.

“This partnership reflects our shared commitment to breaking barriers in mental health treatment and ensuring patients can access the care they need,” said Elizabeth Dosoretz, LCSW, Founder and CEO of Elite DNA Behavioral Health. “Working with Neuronetics allows us to continue advancing our mission to make comprehensive, evidence-based care available in every community we serve.”

The partnership began with a pilot launch in Q4 2025 and is expected to expand throughout 2026, marking a significant milestone in Neuronetics’ strategy to broaden its footprint in mental health networks. The collaboration underscores both companies’ shared commitment to improving accessibility and outcomes for patients seeking innovative, evidence-based neurotherapeutic care.

“Our teams are dedicated to ensuring that every patient receives timely, coordinated, and compassionate care,” said Dr. Omar Rieche, Chief Medical Officer of Elite DNA Behavioral Health. “Partnering with Neuronetics as an extension of our care teams allows us to deliver a more seamless patient experience, expand access to advanced treatment options, and uphold the highest clinical standards across all of our clinics — ensuring that individuals suffering from severe and persistent depression can access every treatment option available to them.”